8th Annual Chfr Symposium

Size: px
Start display at page:

Download "8th Annual Chfr Symposium"

Transcription

1 COVER 8th Annual Chfr Symposium Program and ABSTRACTS September 30 October 01, 2010

2 Center for Heart Failure Research 20ı0 Dear Participant, We are very pleased to welcome you to the 8th Annual CHFR Symposium. We look forward to a very exciting meeting, fruitful discussions and scientific interactions. The Center for Heart Failure Research constitutes a branch of medical research within the Faculty of Medicine at the University of. It is financially supported by the University and the South-Eastern Norway Regional Health Authority (Helse Sør-Øst). The Center represents the concerted action of groups with complementary expertise combining state-ofthe-art gene technology and capabilities to investigate protein function in experimental systems. The systems range from isolated cells and multicellular preparations to integrative physiology in pathophysiological models of heart failure. The clinical research groups of the Center for Heart Failure Research allow for testing of hypotheses in prospective clinical studies. The Center also organizes the PhD School of Heart Research that provides a high quality program specifically aimed at qualifying PhD students for future careers in heart research. The School hosts an annual introductory course as well as workshops for ongoing projects, and it provides a network for collaborations and exchange of methods and ideas within the Center. The Center also organizes the required mid-term evaluation (midtveisevaluering) of the PhD candidates in the field of heart research. We are happy to announce that the is sponsored by the Anders Jahre s Fund for Promotion of Science. Our main aim is to promote and integrate high quality research from bench to bedside in the field of heart failure. Steering committee, Center for Heart Failure Research Geir Øystein Andersen, Harald Arnesen, Dan Atar, Håvard Attramadal, Reidar Bjørnerheim, Thor Edvardsen, Lars Gullestad, John Kjekshus, Finn Olav Levy, Torbjørn Omland, Jan-Bjørn Osnes, Ole M. Sejersted, Ingebjørg Seljeflot, Ivar Sjaastad, Tor Skomedal, Otto Smiseth, Petter Andreas Steen, Guro Valen and Geir Christensen Organizers: Fredrik Swift, Mathis Stokke, Anne Wæhre Page 2

3 Content 04 General information 06 Information for speakers and poster presenters 07 Program 09 Poster sessions 15 Abstracts Poster session I 25 Abstracts Poster session II 36 Abstracts Poster session III 48 Abstracts Poster session IV 59 Abstracts Poster session V 71 List of participants Page 3

4 General information Venue All events take place at, Oslo (www.holmenkollenparkhotel.no). The hotel is nicely located 350 m above sea level, overlooking Oslo. The scientific sessions are held in Saga Hall. Registration On the first day of the meeting please collect your badge and program at the registration desk as soon as possible upon arrival. The registration desk is located near Saga Hall. How to get there? By car: Eı8 South-west (from Drammen/Sandvika): Follow the signs to Ring 3 and Smestad. At Smestad, follow the signs to Holmenkollen. E6/Eı8 South-east (from Gothenburg/Stockholm): Follow the signs to Drammen, through Oslo city centre. Then follow the signs to Ring 3 and Smestad. At Smestad, follow the signs to Holmenkollen. E6 North (Oslo Airport, Gardermoen): After passing the toll booths, keep to the right and head towards Ring 3 Sinsen and Smestad. At Smestad, follow the signs to Holmenkollen. Parking: The hotel offers free parking in designated parking spots before the final approach to the hotel, in addition to indoor parking for a fee in the hotel s parking garage. Price: NOK 20,- per hour, NOK ı50,- per day. With public transport: Attention: Alternative transport by bus from Majorstuen due to construction work on the metro line to Holmenkollen. See below and From the airport: Upon arrival at Oslo Airport, Gardermoen, you can take the Airport Train directly to Oslo Central Station (Oslo S); trains depart every ı0 minutes. Travel time is approximately 20 minutes, and the cost is NOK ı70.00 From the Central Station (Oslo S): Take the metro (T-bane) to Majorstuen. From Majorstuen, bus ıb will take you to Holmenkollen T. Follow the road uphill towards the Holmenkollen National Ski Stadium. It is a ı0 minute walk, and slightly uphill. Taxi from the Central Station (Oslo S): The taxi journey takes approx 20 minutes, and the cost is NOK ı50 250, depending on what time you will be travelling and number of passengers. Airport Taxi: To get special prices by taxi from the Gardermoen Airport directly to the, just contact the Airport Taxi stand, next to the arrival gate inside or pre-order at: Page 4

5 Coffee Coffee, tea and soft drinks will be available in the lobby during breaks. Lunch Lunch is offered on both days of the meeting in Galleriet close to the main entrance. Refund of travel expenses (for invited speakers, chairs and moderators only) Your travel expenses and the costs for the hotel room in Oslo during the meeting will be covered by CHFR. We will pay for your stay at the hotel directly. Please make your own arrangements for flights and transport to/from the airport. For a refund of your travel expenses, please fill out the Refund of travel expenses form downloadable at If your travel costs have been paid by your university or employer, the refund must be given to them. In that case, please ask your employer to send us an invoice for the amount to be refunded. It is compulsory that you provide the IBAN number or bank code of your bank as well as your date of birth. It is also important that you provide the original bills, tickets, etc. Please keep a photocopy of these documents for your own record. The completed forms and the original receipts should be sent to the following address within 2 weeks after the meeting: Elisabeth Engh Seland Det teologiske fakultet Postboks ı023 Blindern N-03ı5 Oslo Norway Page 5

6 Information for speakers and posters presenters Oral presentations Please leave no less than 5 min at the end of your talk for discussion. We ask you to prepare your presentation in PowerPoint. A Windows computer with PowerPoint 2007 installed will be on-site. You must bring your presentation on a USB memory stick or CD at least one hour before your presentation starts. Alternatively, you can your presentation to before September 29, at ı8:00 (Central European Time). If you have any questions regarding the electronic presentations, or if you wish to verify the compatibility of your presentation, please contact: Fredrik Swift Phone: Portrait ı20 x 90 cm Recommended poster size Poster categories: I: Inflammatory mediators and extracellular matrix in heart failure II: Cellular signaling, myocardial hypertrophy and ischemia III: Cellular signaling: myocardial dysfunction IV: Cardiac imaging and arrhythmias V: Markers of cardiovascular disease Poster presentations Posters will be mounted with push-pins, which will be available on-site. Please mount your posters on Thursday morning and according to the number assigned in the program. After the moderated poster sessions, the poster boards will be transferred to the area close to Saga Hall. Please leave your posters mounted until the end of the meeting. The poster should be presented orally in maximally 3 minutes followed by 4-5 minutes discussion. Please do not exceed this time in your presentation since there is only a limited time available for the moderated poster sessions. We encourage you to continue the discussion of the posters in Saga Hall during the breaks of the meeting. A prize of NOK 5000,- will be awarded to the author of the best poster in each session. The criteria are: ı) Novelty of conclusions. 2) Quality of data. 3) Clarity of presentation (purpose, results, conclusions). Page 6

7 Program SEPTEMBER 30, 20ı0 08:00-08:20 Registration 08:20-08:30 Welcome: Geir Christensen, OUHU, UoO Session A: 08:30-09:ı0 09:ı0-09:50 09:50-ı0:05 Cardiomyopathy and inflammation in heart failure Chairs: Otto Smiseth, OUHR, UoO and Theis Tønnessen, OUHU, UoO Christine Seidman, Harvard Medical School, Boston, Massachusetts, USA Cardiomyopathy: From mutation to mechanism Douglas L. Mann, Washington University in St. Louis, Missouri, USA Innate immunity and the failing heart: For whom the cell tolls Break Session B: Moderated poster sessions (ı0:05-ıı:30) I: Inflammatory mediators and extracellular matrix in heart failure Moderators: Arne Yndestad, OUHR and Ingebjørg Seljeflot, OUHU, UoO II: III: IV: Cellular signaling; myocardial hypertrophy and ischemia Moderators: Theis Tønnessen, OUHU, UoO and Terje Larsen, UoT Cellular signaling; myocardial dysfunction Moderators: Øyvind Ellingsen, NTNU and Ivar Sjaastad, OUHU, UoO Cardiac imaging and arrhythmias Moderators: Reidar Bjørnerheim, OUHU and Thor Edvardsen, OUHR, UoO V: Markers of cardiovascular disease Moderator: Helge Røsjø, AUH and Erik Øie, OUHR, Diakonhjemmet Hospital ıı:30-ı2:30 Lunch _ Session C: ı2:30-ı2:50 ı2:50-ı3:30 ı3:30-ı4:00 Publication issues and novel therapeutical approaches Chairs: Dan Atar, OUHU, UoO and Leif Erik Vinge, OUHR Thomas F. Lüscher, University Hospital Zürich, Switzerland How does the ESC journal family cover and prioritize the topic heart failure? Eva van Rooij, miragen Therapeutics, Inc., Boulder, Colorado, USA Oligo-based modulation of mirnas to control cardiovascular disease Break Session D: ı4:00-ı4:40 Vascular disease and cardiac dysfunction Chairs: Harald Arnesen, OUHU, UoO and Thor Edvardsen, OUHR, UoO Boaz D. Rosen, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA Indicators of early myocardial dysfunction in asymptomatic individuals. What was learned from the MESA study? Page 7 ı4:40-ı4:55 ı4:55-ı5:25 Thomas Weiss, Oslo University Hospital Ullevål, Norway Expression of inflammation in adipose tissue as related to cardiovascular disease Thomas F. Lüscher, University Hospital Zürich, Switzerland Endothelial dysfunction in heart failure

8 Program OCTOBER ı, 20ı0 Session E: 08:30-09:ı0 09:ı0-09:40 09:40-ı0:05 Signaling in cardiac disease Chairs: Håvard Attramadal, OUHR, UoO and Finn Olav Levy, UoO Thomas Force, Thomas Jefferson University, Philadelphia, Pennsylvania, USA Re-defining the role of the GSK-3 family in hypertrophy, post-mi remodeling, beta-adrenergic responsiveness, and cardiomyocyte proliferation in the adult heart Martin J. Lohse, University of Würzburg, Germany Cellular signaling in cardiac hypertrophy and failure Break _ Session F: ı0:05-ı0:45 ı0:45-ıı:00 ıı:00-ı2:00 Biomarkers and mechanisms of cardiac disease Chairs: Torbjørn Omland, AUH, UoO and Guro Valen, UoO James Louis Januzzi, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, USA Soluble ST2: Impact in cardiovascular disease? M. Shakil Ahmed, Oslo University Hospital Rikshospitalet, Norway Mechanisms of cardioprotection and myocardial repair - role of matricellular CCN2/CTGF Lunch _ Session G: Arrhythmias and cardiac resuscitation Chairs: Ole M. Sejersted, OUHU, UoO and Petter Andreas Steen, OUHU, UoO ı2:00-ı2:40 Yoram Rudy, Washington University in St. Louis, Missouri, USA The molecular basis of cardiac action potential repolarization OUHU OUHR OUHA AUH UoO UoT NTNU Oslo University Hospital, Ullevål Oslo University Hospital, Rikshospitalet Oslo University Hospital, Aker Akershus University Hospital University of Oslo University of Tromsø Norwegian University of Science and Technology, Trondheim ı2:40-ı2:55 ı2:55-ı3:ı0 ı3:ı0-ı3:40 _ Mathis K. Stokke, Oslo University Hospital Ullevål, Norway Mechanisms underlying non-reentrant ventricular arrhythmias in heart failure Theresa Olasveengen, Oslo University Hospital Ullevål, Norway Intravenous drugs during cardiac arrest Break Session H: Mechanisms of heart failure Chairs: Lars Gullestad, OUHR, UoO and Erik Øie, OUHR, Diakonhjemmet Hospital ı3:40-ı4:20 Heikki Ruskoaho, University of Oulu, Finland Molecular mechanisms of cardiac hypertrophy and heart failure Page 8 ı4:20-ı4:35 ı4:35-ı5:ı5 ı5:ı5-ı5:30 Johannes Bjørnstad, Oslo University Hospital Ullevål, Norway The novel ALK4/5 inhibitor SMı6 preserves cardiac function during pressure overload Douglas F. Larson, University of Arizona, Tucson, Arizona, USA Immune mechanisms associated with arterial hypertension and diastolic dysfunction Presentation of poster prize winners

9 Poster session I Inflammatory mediators and extracellular matrix in heart failure P0ı: Activin A levels are associated with abnormal glucose regulation in patients with myocardial infarction - potential counteracting effects of activin A on inflammation Andersen GØ, Ueland T, Knudsen EC, Scholz H, Yndestad A, Sahraoui A, Smith C, Lekva T, Otterdal K, Halvorsen B, Seljeflot I, Aukrust P P02: Adipose tissue expression of interleukin-ı8 is elevated in metabolic syndrome and independently associated with fasting glucose Weiss TW, Arnesen H, Trøseid M, Kaun C, Hjerkinn EM, Huber K, Wojta J, Seljeflot I P03: Effects of IL-ı8 neutralization in alveolar hypoxia Hillestad V, Larsen KO, Sjaastad I, Nygård S, Skjønsberg OH, Christensen G P04: Identification and characterization of the NLRP3 inflammasome in cardiac fibroblasts Sandanger Ø, Ranheim T, Vinge LE, Florholmen G, Christensen G, Dahl CP, Askevold E, Finsen AV, Rashidi A, Espevik T, Aukrust P, Yndestad A P05: Effects of exercise training on inflammatory markers in chronic heart failure - does etiology matter? Byrkjeland R, Nilsson BB, Westheim AS, Arnesen H, Seljeflot I P06: Proteomic profiling of skeletal muscle and serum from rats with genetically determined high and low VO 2max Bye A, Beisvåg V, Høydal M, Johnsen AB, Alves M, Koch L, Britton S, Wisløff U P07: Reduction in collagen VIII might be involved in transition from compensated hypertrophy to overt heart failure in pressure overload Skrbic B, Bjørnstad JL, Marstein HS, Sjaastad I, Nygård S, Christensen G, Tønnessen T P08: The influence of genetic variations on circulating levels of matrix metalloproteinase-9 in patients with cardiovascular disease Opstad TB, Pettersen AÅ, Åkra S, Weiss T, Arnesen H, Seljeflot I P09: Echocardiographic assessment of the area at risk in mice Redfors B, Scharin Tang M, Miljanovic A, Omerovic E Page 9

10 Poster session II Cellular signaling; myocardial hypertrophy and ischemia Pı0: Integrating microarray gene expression data with prior knowledge about molecular interactions for identification of important heart failure pathways Nygård S, Nygaard V, Clancy T, Bjørnstad J, Skrbic B, Sjaastad I, Tønnessen T, Christensen G, Hovig E Pıı: The Z-disc protein syndecan-4 activates pro-hypertrophic calcineurin-nfat signaling in the myocardium Lunde IG, Finsen AV, Jarstadmarken HO, Kvaløy H, Hasic A, Sjaastad I, Tønnessen T, Skrbic B, Wilcox-Adelman SA, Carlson CR, Christensen G Pı2: Mechanical Stress Increases NFAT Activity During the Hypertrophic Response in Isolated Cardiomyocytes from Neonatal Mice G. Florholmen, I.G. Lunde, C.R. Carlson, G. Christensen Pı3: Mechanical stretch activates the NFAT signaling pathway in cardiac fibroblasts Møller K, Florholmen G, Lunde IG, Behmen D, Carlson CR, Christensen G Pı4: De-phosphorylation - a matter of Phosphatase Specificity Cathrine Husberg, Giulio Agnetti, Geir Christensen, Jennifer Van Eyk Pı5: Protecting the heart through delivering DNA encoding for hemoxygenase-ı in skeletal muscle Bilbija D, Gravning J, Attramadal H, Valen G Pı6: Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial infarction and prevents ischemic heart failure Jørgen Gravning, Stein Ørn, Thor Edvardsen, Vladimir N. Martinov, Cord Manhenke, Kenneth Dickstein, Håvard Attramadal and Mohammed Shakil Ahmed Pı7: New function of Matricellular Protein CCN2/CTGF as Proliferative and Survival Factor for Cardiac Stem Cells. Vladimir N Martinov A, M. Shakil Ahmed, Einar O Vik-Mo, David Kunke, Magnar Bjørås, Håvard Attramadal Pı8: CCN2 Exerts Direct Cytoprotective Actions on Cardiac Myocytes by Activation of the PI3-Kinase/Akt/GSK-3β Signaling Cascade Ingvild Tronstad Moe, Tuyet Anh Pham, M. Shakil Ahmed and Håvard Attramadal Pı9: Mechanisms of attenuated hypertrophic responses to chronic infusion of angiotensin II in Tg-CTGF mice Pham TA, Moe IT, von Lueder T, Ahmed MS, Attramadal H Page 10

11 Poster session III Cellular signaling; myocardial dysfunction P20: The NO/cyclic GMP signalling pathway differentially affects 5-HT 4 - and β ı -AR-mediated inotropic responses in failing ventricle Qvigstad E, Afzal F, Aronsen JM, Moltzau LR, Sjaastad I, Skomedal T, Osnes J-B, Levy FO P2ı: Compartmentation of the cgmp signal causes differential functional responses after CNP and BNP stimulation in failing myocardium Moltzau LR, Aronsen JM, Meier S, Nguyen CHT, Afzal F, Sjaastad I, Skomedal T, Osnes J-B, Levy FO, Qvigstad E P22: C-type natriuretic peptide signalling through NPR-B enhances the β ı -AR signalling both in non-failing and failing rat hearts Meier S, Aronsen JM, Levy FO, Skomedal T, Osnes J-B, Qvigstad Eı P23: Full length cardiac Na + -Ca 2+ exchanger (NCXı) protein is not phosphorylated by protein kinase A (PKA) Wanichawan P, Louch W, Austbø B, Scott JD, Sejersted OM and Carlson CR P24: Alterations in Ca 2+ Sparks and T-tubules Promote Slowed, Dyssynchronous Ca 2+ Release in Chronically Failing Cardiomyocytes Louch WE, Mørk HK, Hougen K, Sjaastad I, and Sejersted OM P25: Slowed cardiomyocyte Ca 2+ release during early heart failure results from alterations in Ca 2+ sparks Jølle GF, Skrbic B, Sjaastad I, Sejersted OM, and Louch WE P26: T-tubule proliferation facilitates trans-sarcolemmal Ca 2+ flux to compensate for declining SR function in Serca2 KO mice Swift F, Enger UH, Jølle GF, Andersson KB, Christensen G, Sejersted OM, and Louch WE P27: Increased oxygen cost for contractile function and decreased oxygen cost for excitation-contraction coupling in mice with inducible cardiomyocyte-specific excision of the Serca2 gene Neoma Boardman, Ole Sejersted, Ivar Sjaastad, Terje S Larsen, Geir Christensen, Ellen Aasum P28: Single dose tamoxifen for Cre-lox gene inactivation minimizes unspecific transcriptional changes and cardiomyopathy in mice. Karina Hougen, Jan Magnus Aronsen, Mathis K. Stokke, Ulla Enger, Ståle Nygård, Kristin B. Andersson, Geir Christensen, Ole M. Sejersted, Ivar Sjaastad P29: Characterization of factors regulating beta 2 -adrenoceptor-mediated contractility in human and rat left ventricle Hussain RI, Melsom CB, Nguyen CH, Qvigstad E, Skomedal T, Osnes JB, Levy FO, Krobert KA Page 11 P30: Prostanoid-mediated inotropic effects are attenuated in failing human and rat ventricular myocardium Riise J, Nguyen C, Hussain RI, Dahl CP, Ege MS, Osnes JB, Skomedal T, Sandnes D, Levy FO & Krobert KA

12 Poster session IV Cardiac imaging and arrhythmias P3ı: No Impact of Atrial Fibrillation on Mortality Risk in Optimally Treated Heart Failure Patients Tveit A, Flønæs B, Aaser E, Korneliussen K, Frøland G, Gullestad L, Grundtvig M P32: Asymmetric Dimethylarginine, Angiotensin Receptor Blockade and Endothelial Recovery after Electrical Cardioversion for Atrial Fibrillation Tveit A, Arnesen H, Smith P, Bratseth V, Seljeflot I P33: Mechanical dispersion and ventricular dysfunction by myocardial strain is related to malignant arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy Kristina Hermann Haugaa, Sebastian Imre Sarvari, Ole Gunnar Anfinsen, Otto A. Smiseth, Erik Kongsgård, Jan P. Amlie, Thor Edvardsen P34: High rate of successful left ventricle lead placement in the target wall region in standard CRT- implantation Köpp U, Gjestvang FT, Eivindson G, Myhre ESP P35: Low rates of left ventricle lead failure by adequate lead selection in CRT-implantation Köpp U, Gjestvang FT, Eivindson G, Myhre ESP P36: Prevalence of Cardiac Arrhythmias in Subjects with Obstructive Sleep Apnea in the General Population: The Akershus Sleep Apnea Project (ASAP) Namtvedt SK, Randby A, Einvik G, Somers VK, Røsjø H, Omland T P37: Cardiac dysfunction in juvenile dermatomyositis Thomas Schwartz, Helga Sanner, Trygve Huseby, Berit Flatø, Ivar Sjaastad P38: Prognostic significance of microvascular obstruction on left ventricular function and infarct size in patients with acute myocardial infarction Shanmuganathan L, Eritsland J, Andersen GØ, Kløw N-E and Hoffmann P P39: Early signs of LV deterioration in an experimental model of sepsis Hestenes S, Skulstad H, Halvorsen PS, Edvardsen T P40: Preserved Sublingual Microcirculation and Compensatory Up-regulated Liver and Kidney Mitochondrial Respiration in Pigs with Myocardial Ischemia and Cardiogenic Shock Kildal A, Sanden E, Stenberg T, How O-J, Chi X, Hagve M, Ytrehus K, Larsen T, Hermansen S and Myrmel T Page 12

13 Poster session V Markers of cardiovascular disease P4ı: Circulating secreted frizzled related protein 3 (sfrp3) predicts outcome in patients with chronic heart failure Askevold ET, Dahl CP, Broch K, Aakhus S, Yndestad A, Gullestad L, Aukrust P, Ueland T P42: Plasma levels of Wnt inhibitory factor-ı (WIF-ı) are elevated and predict mortality in symptomatic aortic stenosis Erik Tandberg Askevold, Lars Gullestad, Svend Aakhus, Ole G. Solberg, Pål Aukrust, Thor Ueland P43: N-terminal pro-b-type natriuretic peptide is associated with the incidence of sudden cardiac death in patients with stable coronary artery disease and preserved left ventricular systolic function Røysland R, Omland T, Sabatine MS, Hsia J, Solomon SD, Christophi CA, Rice MM, Jablonski KA, Domanski MJ, Rouleau JL, Pfeffer MA, Braunwald E, for the PEACE Investigators P44: Prognostic value of osteoprotegerin in chronic heart failure: the GISSI-HF trial Røysland R, Masson S, Omland T, Milani V, Bjerre M, Flyvbjerg A, Di Tano G, Maggioni AP, Tavazzi L, Latini R, on behalf of the GISSI-HF Investigators. P45: Elevated serum osteoprotegerin levels measured early after an acute ST-elevation myocardial infarction predicts final infarct size. Andersen GØ, Knudsen EC, Aukrust P, Yndestad A, Øie E, Müller C, Seljeflot I, Ueland T P46: The Influence of Intracoronary Injection of Mononuclear Bone Marrow Cells on Prothrombotic Markers in Patients with Acute Myocardial Infarction Solheim S, Seljeflot I, Lunde K, Aakhus S, Bratseth V, Forfang K, Arnesen H P47: Prothrombotic Markers in Patients with Acute Myocardial Infarction and Left Ventricular Thrombus Formation Treated with Dual Antiplatelet Therapy Solheim S, Arnesen H, Lunde K, Aakhus S, Bjørnerheim R, Bratseth V, Forfang K, Seljeflot I P48: Circulating PAI-ı activity and t-pa antigen are associated with newly diagnosed abnormal glucose regulation in patients with acute STEMI. Knudsen EC, Seljeflot I, Abdelnoor M, Eritsland J, Mangschau A, Arnesen H, Andersen GØ P49: Prognostic value of oral glucose tolerance testing in patients with a primary PCI treated STEMI. Knudsen EC, Seljeflot I, Abdelnoor M, Eritsland J, Mangschau A, Arnesen H, Andersen GØ Page 13 P50: Predictors of Troponin Elevation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Høiseth AD, Neukamm A, Brekke PH, Omland T, Søyseth V P5ı: Elevated level of Aldosterone during acute exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) predicts post discharge mortality. Høiseth AD, Neukamm A, Brekke PH, Omland T, Søyseth V

9 th AnnuAl chfr symposium

9 th AnnuAl chfr symposium 9 th AnnuAl chfr symposium PROGRAM AND ABSTRACTS September 15 16, 2011 Holmenkollen Park Hotel Rica, Oslo, Norway Center for Heart Failure Research content dear Participant We are very pleased to welcome

More information

chfr PROGRAM AND ABSTRACTS OSLO, NOR Y

chfr PROGRAM AND ABSTRACTS OSLO, NOR Y 10 th AnnuAl chfr symposium PROGRAM AND ABSTRACTS Holmenkollen Park Hotel Rica september 20 21, 2012 OSLO, NORY content 3 Preface 4 General information 5 Information for speakers and poster presenters

More information

Version 1 2015. Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen

Version 1 2015. Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen Version 1 2015 Module guide International Master Program Cardiovascular Science University of Göttingen Part 1 Theoretical modules Synopsis The Master program Cardiovascular Science contains four theoretical

More information

RITMIR024 - STEM CELL RESEARCH IN CARDIOLOGY

RITMIR024 - STEM CELL RESEARCH IN CARDIOLOGY 1. SCOPE AND METHODOLOGY 2. REPORT SYNOPSIS 2.1 General Definitions Myoblasts Pluripotent Cells Multipotent Cells Progenitor Cells Role of Stem Cells in Repairing the Heart Stem Cell Therapy Stem Cells

More information

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) By Prof. Dr. Helmy A. Bakr Mansoura Universirty 2014 AF Classification: Mechanisms of AF : Selected Risk Factors and Biomarkers for AF: WHY AF? 1. Atrial fibrillation

More information

Diagnosis Code Crosswalk : ICD-9-CM to ICD-10-CM Cardiac Rhythm and Heart Failure Diagnoses

Diagnosis Code Crosswalk : ICD-9-CM to ICD-10-CM Cardiac Rhythm and Heart Failure Diagnoses Diagnosis Code Crosswalk : to 402.01 Hypertensive heart disease, malignant, with heart failure 402.11 Hypertensive heart disease, benign, with heart failure 402.91 Hypertensive heart disease, unspecified,

More information

NEW ADVANCES IN MYOCARDIAL INFARCTION THERAPY: THE REGENERATION APPROACH

NEW ADVANCES IN MYOCARDIAL INFARCTION THERAPY: THE REGENERATION APPROACH NEW ADVANCES IN MYOCARDIAL INFARCTION THERAPY: THE REGENERATION APPROACH Giovanni Esposito, MD, PhD Dipartimento di Cardiologia, Cardiochirurgia ed Emergenze Cardiovascolari Laboratorio di Emodinamica

More information

STEM CELL FELLOWSHIP

STEM CELL FELLOWSHIP Module I: The Basic Principles of Stem Cells 1. Basics of Stem Cells a. Understanding the development of embryonic stem cells i. Embryonic stem cells ii. Embryonic germ cells iii. Differentiated stem cell

More information

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized

More information

Lecture Outline. Cardiovascular Physiology. Cardiovascular System Function. Functional Anatomy of the Heart

Lecture Outline. Cardiovascular Physiology. Cardiovascular System Function. Functional Anatomy of the Heart Lecture Outline Cardiovascular Physiology Cardiac Output Controls & Blood Pressure Cardiovascular System Function Functional components of the cardiovascular system: Heart Blood Vessels Blood General functions

More information

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains

More information

ACLS PHARMACOLOGY 2011 Guidelines

ACLS PHARMACOLOGY 2011 Guidelines ACLS PHARMACOLOGY 2011 Guidelines ADENOSINE Narrow complex tachycardias or wide complex tachycardias that may be supraventricular in nature. It is effective in treating 90% of the reentry arrhythmias.

More information

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process

More information

COVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION

COVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION COVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION Question: How should the EGBS Coverage Guidance regarding ablation for atrial fibrillation be applied to the Prioritized List? Question source: Evidence

More information

Hypertension and cardiovascular (CV) ageing Bridging basic research and clinical science

Hypertension and cardiovascular (CV) ageing Bridging basic research and clinical science Title: Hypertension and cardiovascular (CV) ageing Bridging basic research and clinical science Prior to seminar: Participants are selected by the organizing committee based on curriculum vitae and application

More information

Evolving Challenges in Promoting Cardiovascular Health. November 4-5, 2011, BARCELONA. Final Agenda Feb 2011

Evolving Challenges in Promoting Cardiovascular Health. November 4-5, 2011, BARCELONA. Final Agenda Feb 2011 Evolving Challenges in Promoting Cardiovascular Health November 4-5, 2011, BARCELONA Final Agenda Feb 2011 SATELLITE PUBLIC LECTURE (LAY PUBLIC): Thursday, November 3, 2011 7:00 8:30 PM Health and Life

More information

CHFR SYMPOSIUM Holmenkollen Park Hotel Rica October 11-12, 2007

CHFR SYMPOSIUM Holmenkollen Park Hotel Rica October 11-12, 2007 5th Annual CHFR SYMPOSIUM Holmenkollen Park Hotel Rica October 11-12, 2007 PROGRAM AND ABSTRACTS Center for Heart Failure Research 2007 Dear Friends and Colleagues, We warmly welcome you to our 5th Annual

More information

1p36 and the Heart. John Lynn Jefferies, MD, MPH, FACC, FAHA

1p36 and the Heart. John Lynn Jefferies, MD, MPH, FACC, FAHA 1p36 and the Heart John Lynn Jefferies, MD, MPH, FACC, FAHA Director, Advanced Heart Failure and Cardiomyopathy Services Associate Professor, Pediatric Cardiology and Adult Cardiovascular Diseases Associate

More information

Vitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model

Vitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model Vitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model Robyn Balden & Farida Sohrabji Texas A&M Health Science Center- College of Medicine ISC

More information

Hello. I would like to think everyone for coming this morning. I m going to talk about heart disease in pregnancy.

Hello. I would like to think everyone for coming this morning. I m going to talk about heart disease in pregnancy. Hello. I would like to think everyone for coming this morning. I m going to talk about heart disease in pregnancy. 1 I have a few objectives for this talk. First, we ll review the normal, anticipated chambers

More information

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Heart Failure Center Hadassah University Hospital Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Israel Gotsman MD The Heart Failure Center, Heart Institute Hadassah University

More information

Potential Causes of Sudden Cardiac Arrest in Children

Potential Causes of Sudden Cardiac Arrest in Children Potential Causes of Sudden Cardiac Arrest in Children Project S.A.V.E. When sudden death occurs in children, adolescents and younger adults, heart abnormalities are likely causes. These conditions are

More information

Automatic External Defibrillators

Automatic External Defibrillators Last Review Date: May 27, 2016 Number: MG.MM.DM.10dC2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth

More information

Innovation Platform: Sudden Cardiac Death

Innovation Platform: Sudden Cardiac Death Innovation Platform: Sudden Cardiac Death Prof. dr. Bart Loeys CRC Antwerp General Assembly VzW Board of Directors Strategic Advisory Board Staff: 1 executive director 1 ICT manager 1 financial administration

More information

Heart Disease: Diagnosis & Treatment

Heart Disease: Diagnosis & Treatment How I Treat Cardiology Peer Reviewed Heart Disease: Diagnosis & Treatment Amara Estrada, DVM, DACVIM (Cardiology) University of Florida Background Clinical heart disease is the stage of disease when a

More information

Danish Cardiovascular Research Academy and Faculty of Health Sciences University of Copenhagen

Danish Cardiovascular Research Academy and Faculty of Health Sciences University of Copenhagen Danish Cardiovascular Research Academy and Faculty of Health Sciences University of Copenhagen PhD course: Cardiac arrhythmias - Aim and content: Cardiac arrhythmia represents a wide spectrum of abnormalities

More information

Cardiovascular System & Its Diseases. Lecture #4 Heart Failure & Cardiac Arrhythmias

Cardiovascular System & Its Diseases. Lecture #4 Heart Failure & Cardiac Arrhythmias Cardiovascular System & Its Diseases Lecture #4 Heart Failure & Cardiac Arrhythmias Dr. Derek Bowie, Department of Pharmacology & Therapeutics, Room 1317, McIntyre Bldg, McGill University derek.bowie@mcgill.ca

More information

Atrial Fibrillation Based on ESC Guidelines. Moshe Swissa MD Kaplan Medical Center

Atrial Fibrillation Based on ESC Guidelines. Moshe Swissa MD Kaplan Medical Center Atrial Fibrillation Based on ESC Guidelines Moshe Swissa MD Kaplan Medical Center Epidemiology AF affects 1 2% of the population, and this figure is likely to increase in the next 50 years. AF may long

More information

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with

More information

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic

More information

INHERIT. The Lancet Diabetes & Endocrinology In press

INHERIT. The Lancet Diabetes & Endocrinology In press INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy a Randomized Intervention Trial with losartan Anna Axelsson, Kasper Iversen, Niels Vejlstrup, Carolyn

More information

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.

More information

B Cells and Antibodies

B Cells and Antibodies B Cells and Antibodies Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School Lecture outline Functions of antibodies B cell activation; the role of helper T cells in antibody production

More information

Cardiovascular Regulation

Cardiovascular Regulation Cardiovascular Regulation Regulation of hemodynamics occurs via local autoregulation, neural control and hormones. Spring 2004 1 Autoregulation of Blood Flow Local regulation of blood flow occurs by vasoconstriction

More information

Introduction. Pathogenesis of type 2 diabetes

Introduction. Pathogenesis of type 2 diabetes Introduction Type 2 diabetes mellitus (t2dm) is the most prevalent form of diabetes worldwide. It is characterised by high fasting and high postprandial blood glucose concentrations (hyperglycemia). Chronic

More information

Heart Pump and Cardiac Cycle. Faisal I. Mohammed, MD, PhD

Heart Pump and Cardiac Cycle. Faisal I. Mohammed, MD, PhD Heart Pump and Cardiac Cycle Faisal I. Mohammed, MD, PhD 1 Objectives To understand the volume, mechanical, pressure and electrical changes during the cardiac cycle To understand the inter-relationship

More information

PhD-course. Danish Cardiovascular Research Academy and the Nordic Medical Research Councils

PhD-course. Danish Cardiovascular Research Academy and the Nordic Medical Research Councils PhD-course Danish Cardiovascular Research Academy and the Nordic Medical Research Councils Title of the course: Hypertension and cardiovascular ageing Bridging basic research and clinical science Aim:

More information

Department of BioScience Technology Chung Yuan Christian University 2015/08/13

Department of BioScience Technology Chung Yuan Christian University 2015/08/13 Department of BioScience Technology Chung Yuan Christian University 2015/08/13 Cancer Cells Cancer, the 1st leading cause of death, is an example of a disease that arises from abnormalities in cell function

More information

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa 1999. Objectives. No disclosures, no conflicts

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa 1999. Objectives. No disclosures, no conflicts Cardiac Rehabilitation: From the other side of the glass door No disclosures, no conflicts Charles X. Kim, MD, FACC, ABVM Objectives 1. Illustrate common CV benefits of CV rehab in real world practice.

More information

1 Congestive Heart Failure & its Pharmacological Management

1 Congestive Heart Failure & its Pharmacological Management Harvard-MIT Division of Health Sciences and Technology HST.151: Principles of Pharmocology Instructor: Prof. Keith Baker 1 Congestive Heart Failure & its Pharmacological Management Keith Baker, M.D., Ph.D.

More information

Heart Failure EXERCISES. Ⅰ. True or false questions (mark for true question, mark for false question. If it is false, correct it.

Heart Failure EXERCISES. Ⅰ. True or false questions (mark for true question, mark for false question. If it is false, correct it. Heart Failure EXERCISES Ⅰ. True or false questions (mark for true question, mark for false question. If it is false, correct it. ) 1. Heart rate increase is a kind of economic compensation, which should

More information

Mechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies. Biochemistry Journal. August 1, 2007 405, pp.

Mechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies. Biochemistry Journal. August 1, 2007 405, pp. Mechanism of short-term ERK activation by electromagnetic fields at mobile phone frequencies 1 Biochemistry Journal August 1, 2007 405, pp. 559 568 Joseph Friedman, Sarah Kraus, Yirmi Hauptman, Yoni Schiff

More information

30 th Annual meeting of the Ohio Physiological Society held at the University of Toledo College of Medicine and Life Sciences

30 th Annual meeting of the Ohio Physiological Society held at the University of Toledo College of Medicine and Life Sciences 30 th Annual meeting of the Ohio Physiological Society held at the University of Toledo College of Medicine and Life Sciences Dr. Lance Stechschulte Postdoctoral Fellow Department of Physiology and Pharmacology

More information

Central Florida Research Update

Central Florida Research Update Central Florida Research Update Ayala, Julio, PhD, Sanford-Burnham Medical Research Institute, Orlando, Florida Anorectic Mechanisms of Glp1r Agonists Obesity Jan 1, 2014 Dec 31, 2018 Integrated Physiology,

More information

Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona

Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona Areas to be covered Historical, current, and future treatments for various cardiovascular disease: Atherosclerosis (Coronary

More information

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational

More information

Universitätsklinik für Kardiologie. Test. Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie thomas.suter@insel.ch 1

Universitätsklinik für Kardiologie. Test. Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie thomas.suter@insel.ch 1 Test Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie thomas.suter@insel.ch 1 Heart Failure - Definition European Heart Journal (2008) 29, 2388 2442 Akute Herzinsuffizienz Diagnostik und

More information

9 th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C) 9th International Symposium

9 th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C) 9th International Symposium 9 th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C) 9th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C) Szeged,

More information

Coxib s have taught us a lesson to explore more diligently the molecular and cellular pathways of inflammation

Coxib s have taught us a lesson to explore more diligently the molecular and cellular pathways of inflammation Coxib s have taught us a lesson to explore more diligently the molecular and cellular pathways of inflammation Steffen Gay Arthritis linked to cardiovascular disease CV Death Osteoarthritis CHF Rheumatoid

More information

INTRODUCTION TO EECP THERAPY

INTRODUCTION TO EECP THERAPY INTRODUCTION TO EECP THERAPY is an FDA cleared, Medicare approved, non-invasive medical therapy for the treatment of stable and unstable angina, congestive heart failure, acute myocardial infarction, and

More information

Atrial Fibrillation Management Across the Spectrum of Illness

Atrial Fibrillation Management Across the Spectrum of Illness Disclosures Atrial Fibrillation Management Across the Spectrum of Illness NONE Barbara Birriel, MSN, ACNP-BC, FCCM The Pennsylvania State University Objectives AF Discuss the pathophysiology, diagnosis,

More information

Diagnostic and Therapeutic Procedures

Diagnostic and Therapeutic Procedures Diagnostic and Therapeutic Procedures Diagnostic and therapeutic cardiovascular s are central to the evaluation and management of patients with cardiovascular disease. Consistent with the other sections,

More information

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die

More information

Treatment of cardiogenic shock

Treatment of cardiogenic shock ACUTE HEART FAILURE AND COMORBIDITY IN THE ELDERLY Treatment of cardiogenic shock Christian J. Wiedermann, M.D., F.A.C.P. Associate Professor of Internal Medicine, Medical University of Innsbruck, Austria

More information

Summer School 2011 Berlin SFB Transregio 19

Summer School 2011 Berlin SFB Transregio 19 Summer School 2011 Berlin SFB Transregio 19 27th October 29th October 2011 Molecular Mechanisms and Consequences of Inflammatory Cardiomyopathy: State of the Art and Future Challenges Welcome Address

More information

Brooklyn Stroke Symposium 2015

Brooklyn Stroke Symposium 2015 Brooklyn Stroke Symposium 2015 May 28, 2015 Brooklyn Public Library Grand Army Plaza Sponsored by Keynote Presentations Sleep Apnea and Stroke: More than a Snore Devin L. Brown, M.D., M.S. Professor of

More information

SECOND CARDIOLOGY JOINT SEMINAR. Rome, April 12-13, 2012. Cardiovascular Center OLV Clinic Aalst Belgium. and

SECOND CARDIOLOGY JOINT SEMINAR. Rome, April 12-13, 2012. Cardiovascular Center OLV Clinic Aalst Belgium. and SECOND CARDIOLOGY JOINT SEMINAR Rome, April 12-13, 2012 Cardiovascular Center OLV Clinic Aalst Belgium and Cardiology Faculty of Medicine and Psychology Sapienza University, Rome, Italy Cardiology Sacred

More information

Hypertrophic and Dilated Cardiomyopathy. Rahul Deo, MD PHD Assistant Professor Division of Cardiology, UCSF Principal Investigator, CVRI

Hypertrophic and Dilated Cardiomyopathy. Rahul Deo, MD PHD Assistant Professor Division of Cardiology, UCSF Principal Investigator, CVRI Hypertrophic and Dilated Cardiomyopathy Rahul Deo, MD PHD Assistant Professor Division of Cardiology, UCSF Principal Investigator, CVRI Outline Definitions Epidemiology: the scope of the problem Genetics

More information

CVI s 2nd Annual New Paradigms in Arrhythmia Management: The Good, the Bad and the Ugly

CVI s 2nd Annual New Paradigms in Arrhythmia Management: The Good, the Bad and the Ugly Please join us for CVI s 2nd Annual New Paradigms in Arrhythmia Management: The Good, the Bad and the Ugly Sunday, April 21, 2013 Loews Philadelphia Hotel Register today and be entered to win a FREE Apple

More information

The-First-In-Man Randomized Trial of a ß3- adrenoceptor Agonist in Chronic Heart Failure BEAT-HF

The-First-In-Man Randomized Trial of a ß3- adrenoceptor Agonist in Chronic Heart Failure BEAT-HF The-First-In-Man Randomized Trial of a ß3- adrenoceptor Agonist in Chronic Heart Failure Henning Bundgaard, Anna Axelsson, Jakob H Thomsen, Mathias Sørgaard, Klaus Kofoed, Nana Køber, Rasmus B Hasselbalch,

More information

Jeffrey M. Carlton Heart & Vascular Institute Presents

Jeffrey M. Carlton Heart & Vascular Institute Presents Jeffrey M. Carlton Heart & Vascular Institute Presents 6 th ANNUAL CARDIOLOGY UPDATE: NEW DEVELOPMENTS Program Director: Robert and Georgia Roth Endowed Chair for Excellence in Cardiac Care Saturday, September

More information

How to train the cardiovascular patient? Physical activity in patients with heart disease: how much is good enough?

How to train the cardiovascular patient? Physical activity in patients with heart disease: how much is good enough? How to train the cardiovascular patient? Physical activity in patients with heart disease: how much is good enough? Per Anton Sirnes MD.Phd.FESC Moss, Norway Chair, ESC Council on Cardiology Practice Conflicts

More information

Medical Therapies Limited EGM Presentation

Medical Therapies Limited EGM Presentation Medical Therapies Limited EGM Presentation Maria Halasz Chief Executive Officer 5 May 2009 1 Agenda 1. Company information 2. Recent developments 3. Business strategy 4. Key value inflection points for

More information

The Sepsis Puzzle: Identification, Monitoring and Early Goal Directed Therapy

The Sepsis Puzzle: Identification, Monitoring and Early Goal Directed Therapy The Sepsis Puzzle: Identification, Monitoring and Early Goal Directed Therapy Cindy Goodrich RN, MS, CCRN Content Description Sepsis is caused by widespread tissue injury and systemic inflammation resulting

More information

Approach to Abnormal Liver Tests

Approach to Abnormal Liver Tests Approach to Abnormal Liver Tests Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of Gastroenterology and Hepatology Indiana University School

More information

Diabetes mellitus. Lecture Outline

Diabetes mellitus. Lecture Outline Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized

More information

Rudolf de Boer. Paula Da Costa Martins. Ralph van Oort. Kevin Vernooij. Daniël Pijnappels. Lynda Juffermans. Toon van Veen. Peter van der Meer

Rudolf de Boer. Paula Da Costa Martins. Ralph van Oort. Kevin Vernooij. Daniël Pijnappels. Lynda Juffermans. Toon van Veen. Peter van der Meer Paula Da Costa Martins Ralph van Oort Lynda Juffermans Kevin Vernooij Daniël Pijnappels Toon van Veen Rudolf de Boer Linda van Laake Kim Van der Heiden Matthijs Boekholdt Peter van der Meer Blanche Schroen

More information

5 Frequently Asked Questions About Adult Stem Cell Research

5 Frequently Asked Questions About Adult Stem Cell Research 5 Frequently Asked Questions About Adult Stem Cell Research Stem cells are often referred to in the sociopolitical realm with some level of controversy and beyond that, some level of confusion. Many researchers

More information

on behalf of the AUGMENT-HF Investigators

on behalf of the AUGMENT-HF Investigators One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas

More information

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION

More information

5/14/2014. How do you evaluate hypertrophic cardiomyopathy? How do you do you diagnose hypertrophic cardiomyopathy?

5/14/2014. How do you evaluate hypertrophic cardiomyopathy? How do you do you diagnose hypertrophic cardiomyopathy? Hypertrophic Cardiomyopathy: Clinical and Genetic Evaluation Hypertrophic Cardiomyopathy: Clinical and Genetic Evaluation Ray E. Hershberger, MD Professor of Medicine i Director, Division of Human Genetics

More information

Anatomi & Fysiologi 060301. The cardiovascular system (chapter 20) The circulation system transports; What the heart can do;

Anatomi & Fysiologi 060301. The cardiovascular system (chapter 20) The circulation system transports; What the heart can do; The cardiovascular system consists of; The cardiovascular system (chapter 20) Principles of Anatomy & Physiology 2009 Blood 2 separate pumps (heart) Many blood vessels with varying diameter and elasticity

More information

Genetic Predisposition to Ventricular Arrhythmias and. Sudden Death in Hypertrophic Cardiomyopathy

Genetic Predisposition to Ventricular Arrhythmias and. Sudden Death in Hypertrophic Cardiomyopathy Dott.ssa Daria Santini Dottorato di Ricerca in Medicina Sperimentale Genetic Predisposition to Ventricular Arrhythmias and Sudden Death in Hypertrophic Cardiomyopathy Background Hypertrophic cardiomyopathy

More information

Rikshospitalet, University of Oslo

Rikshospitalet, University of Oslo Rikshospitalet, University of Oslo Controversies in the optimal management of ischemic heart failure From myocardial infarction to heart failure How do we prevent this? European Society of Cardiology 23.05.2011

More information

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG

More information

Section Four: Pulmonary Artery Waveform Interpretation

Section Four: Pulmonary Artery Waveform Interpretation Section Four: Pulmonary Artery Waveform Interpretation All hemodynamic pressures and waveforms are generated by pressure changes in the heart caused by myocardial contraction (systole) and relaxation/filling

More information

2nd MuscleTech Network Workshop. From translational Research to translational Medicine. CONCLUSIONS AND CLOSING REMARKS Dr.

2nd MuscleTech Network Workshop. From translational Research to translational Medicine. CONCLUSIONS AND CLOSING REMARKS Dr. 2nd MuscleTech Network Workshop. From translational Research to translational Medicine. CONCLUSIONS AND CLOSING REMARKS Dr. Carles Pedret MUSCLE AND TENDON WORKSHOP HEALTH AND GENERAL POPULATION SPORTS

More information

J D R F R E Q U E S T S L E T T E R S O F I N T E N T F O R : B I O M AR K E R S O F P AN C R E A T I C B E T A C E L L S T R E S S AN D H E AL T H

J D R F R E Q U E S T S L E T T E R S O F I N T E N T F O R : B I O M AR K E R S O F P AN C R E A T I C B E T A C E L L S T R E S S AN D H E AL T H J D R F R E Q U E S T S L E T T E R S O F I N T E N T F O R : B I O M AR K E R S O F P AN C R E A T I C B E T A C E L L S T R E S S AN D H E AL T H PURPOSE JDRF, the world s leading non-profit organization

More information

Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time

Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time Robert Chilton DO, FACOI, FACC, FAHA Professor of Medicine University of Texas Health Science Center Director

More information

Resuscitation in congenital heart disease. Peter C. Laussen MBBS FCICM Department Critical Care Medicine Hospital for Sick Children Toronto

Resuscitation in congenital heart disease. Peter C. Laussen MBBS FCICM Department Critical Care Medicine Hospital for Sick Children Toronto Resuscitation in congenital heart disease Peter C. Laussen MBBS FCICM Department Critical Care Medicine Hospital for Sick Children Toronto Evolution of Congenital Heart Disease Extraordinary success: Overall

More information

SPONSORSHIP AND EXHIBITOR INVITATION

SPONSORSHIP AND EXHIBITOR INVITATION Geriatric medicine for future Europeans Successful ageing creates new challenges SPONSORSHIP AND EXHIBITOR INVITATION Oslo, Norway, 16 18 September 2015 www.eugms.org/2015 Dear Sir/Madam, On behalf of

More information

Inpatient Heart Failure Management: Risks & Benefits

Inpatient Heart Failure Management: Risks & Benefits Inpatient Heart Failure Management: Risks & Benefits Dr. Kenneth L. Baughman Professor of Medicine Harvard Medical School Director, Advanced Heart Disease Section Brigham & Women's Hospital Harvard Medical

More information

Extrarenal Manifestations of Polycystic Kidney Disease Part Two of Three

Extrarenal Manifestations of Polycystic Kidney Disease Part Two of Three Online Slide/Audio Symposium 10th Annual Conference on Polycystic Kidney Disease, June 1999. Selected Talks. Web presentation sponsored by an unrestricted educational grant from Sigma-Tau Pharmaceuticals

More information

Long term follow up after CA

Long term follow up after CA Long term follow up after CA Lund 31.05.2013 Espen Rostrup Nakstad Oslo University Hospital, Norway handout - page 1 of 9 handout - page 2 of 9 NORCAST Unexpected Cardiac Arrest Europe: 700.000 / year

More information

Exchange solutes and water with cells of the body

Exchange solutes and water with cells of the body Chapter 8 Heart and Blood Vessels Three Types of Blood Vessels Transport Blood Arteries Carry blood away from the heart Transport blood under high pressure Capillaries Exchange solutes and water with cells

More information

THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points

THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points December 2008 (Vol. 1, Issue 3, pages 36-40) THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES By Sophie Lotersztajn, PhD, Ariane Mallat, MD, PhD Inserm U841, Hôpital Henri Mondor,

More information

ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY. Guidelines for Use of Intravenous Isoproterenol

ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY. Guidelines for Use of Intravenous Isoproterenol ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY Guidelines for Use of Intravenous Isoproterenol Major Indications Status Asthmaticus As a last resort for

More information

Finnish Society of Toxicology 34th Annual Symposium 13-14.5.2013 Orion Pharma, Espoo, Finland PREDICTIVE TOXICOLOGY AND DRUG SAFETY TESTING

Finnish Society of Toxicology 34th Annual Symposium 13-14.5.2013 Orion Pharma, Espoo, Finland PREDICTIVE TOXICOLOGY AND DRUG SAFETY TESTING Finnish Society of Toxicology 34th Annual Symposium 13-14.5.2013 Orion Pharma, Espoo, Finland PREDICTIVE TOXICOLOGY AND DRUG SAFETY TESTING Sponsors collaborators: Day 1, Monday 13 May 2013 8:30-9:30 Registration

More information

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3 1. Name of the Procedure: Coronary Balloon Angioplasty 2. Select the Indication from the drop down of various indications

More information

24 th Annual Conference on Cardiovascular Nursing

24 th Annual Conference on Cardiovascular Nursing 24 th Annual Conference on Cardiovascular Nursing Presented by the American Heart Association s Boston Cardiovascular Nursing Committee Wednesday, April 2, 2014 7:00 am - 3:45 pm Boston Marriott Newton,

More information

Program Dag van Biofysica & Biomedische Technologie 13 November Nijmegen

Program Dag van Biofysica & Biomedische Technologie 13 November Nijmegen Program Dag van Biofysica & Biomedische Technologie 13 November Nijmegen Linnaeusgebouw, Heyendaalseweg 137, Campus Radboud University 9.30 Coffee and registration 10.00 Welcome Raymond van Ee, president

More information

Risk Factors of chronic complex co-morbidities. Aldo Pietro Maggioni, MD ANMCO Research Center Firenze, Italy

Risk Factors of chronic complex co-morbidities. Aldo Pietro Maggioni, MD ANMCO Research Center Firenze, Italy Risk Factors of chronic complex co-morbidities Aldo Pietro Maggioni, MD ANMCO Research Center Firenze, Italy Statement 1 In real world practice (and in clinical trials), complex co-morbidities are the

More information

Vasopressors. Judith Hellman, M.D. Associate Professor Anesthesia and Perioperative Care University of California, San Francisco

Vasopressors. Judith Hellman, M.D. Associate Professor Anesthesia and Perioperative Care University of California, San Francisco Vasopressors Judith Hellman, M.D. Associate Professor Anesthesia and Perioperative Care University of California, San Francisco Overview Define shock states Review drugs commonly used to treat hypotension

More information

SECTION I: Request. SECTION II: Need. Program Description

SECTION I: Request. SECTION II: Need. Program Description SECTION I: Request This is a formal request for the Utah CARMA Center to be formally recognized by the University of Utah as a large, collaborative medical and academic center whose focus is on comprehensive

More information

How to get to SINTEF MiNaLab in Oslo Address: Gaustadalléen 23 C, 0373 Oslo

How to get to SINTEF MiNaLab in Oslo Address: Gaustadalléen 23 C, 0373 Oslo How to get to MiNaLab in Oslo Address: Gaustadalléen 23 C, 0373 Oslo GPS coordinates: N59,943728; E10,718136 From Oslo city centre by public transport: Take the metro line 3, 4 or 6 direction west or tram

More information

Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment

Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment What does that mean for you? Your healthcare provider has determined that you may be at risk for cardiovascular disease (CVD).

More information

Decreasing Sepsis Mortality at the University of Colorado Hospital

Decreasing Sepsis Mortality at the University of Colorado Hospital Decreasing Sepsis Mortality at the University of Colorado Hospital Maureen Dzialo, RN, BSN - Nurse Manager, Cardiac Intensive Care Unit Olivia Kerveillant, RN Clinical Nurse III, Medical Intensive Care

More information

Multiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden

Multiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden Multiple comorbidities: additive and predictive of cardiovascular risk Peter M. Nilsson Lund University University Hospital Malmö, Sweden Clinical outcomes: major complications of CVD Heart Attack/ACS

More information

Subject Index. Bariatric surgery, obesity management 134

Subject Index. Bariatric surgery, obesity management 134 Subject Index Acromegaly, PCOS differential diagnosis 149, 150, 154, 155 Adipokines, see specific adipokines Adiponectin, metabolic syndrome role 41 43 Adolescents, PCOS diagnosis 16, 17 Adrenal hyperplasia,

More information